http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Pavan Dhoble ),( Philip Abraham ),( Devendra Desai ),( Anand Joshi ),( Tarun Gupta ),( Shachish Doctor ),( Anand Deshpande ),( Rajeshwari Basavanna ) 대한소화기기능성질환·운동학회 2021 Journal of Neurogastroenterology and Motility (JNM Vol.27 No.4
Background/Aims Most patients with irritable bowel syndrome (IBS) report food-related aggravation of symptoms. Wheat/gluten is one of the most commonly incriminated. We studied the prevalence of self-reported wheat sensitivity in patients with IBS and in a healthy population from a region in India consuming mixed-cereal diets, correlated it with serological and human leukocyte antigen (HLA) markers of celiac disease, and evaluated the response to a wheat-free diet. Methods We surveyed 204 patients with IBS and 400 healthy persons for self-reported wheat sensitivity. Testing for IgA anti-tissue transglutaminase and HLA DQ2 or DQ8 was done in individuals who reported wheat sensitivity. Consenting persons with wheat sensitivity were put on wheat-free diet and monitored for symptom change. Results Twenty-three of 204 patients with IBS (11.3%) and none of the healthy subjects self-reported wheat sensitivity. Of 23 patients, 14 (60.9%) were positive for HLA DQ2 or DQ8 and none for anti-tissue transglutaminase antibody. After 6 weeks on wheat-free diet, all 19 participating patients reported clinical improvement; fewer patients had bloating, diarrhea, constipation, and easy fatigue. Conclusions Eleven percent of patients with IBS self-reported wheat sensitivity. None of them had positive celiac serology; 60.9% were positive for HLA DQ2 and DQ8, suggesting a possible genetic basis. All of them improved symptomatically on a wheat-free diet. (J Neurogastroenterol Motil 2021;27:596-601)
( Ajit Sood ),( Vineet Ahuja ),( Vandana Midha ),( Saroj Kant Sinha ),( C. Ganesh Pai ),( Saurabh Kedia ),( Varun Mehta ),( Sawan Bopanna ),( Philip Abraham ),( Rupa Banerjee ),( Shobna Bhatia ),( Kar 대한장연구학회 2020 Intestinal Research Vol.18 No.4
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)
Second Asian Consensus on Irritable Bowel Syndrome
Kok-Ann Gwee,Sutep Gonlachanvit,Uday C Ghoshal,Andrew S B Chua,Hiroto Miwa,Justin Wu,Young-Tae Bak,Oh Young Lee,Ching-Liang Lu,Hyojin Park,Minhu Chen,Ari F Syam,Philip Abraham,Jose Sollano,Chi-Sen Cha 대한소화기 기능성질환∙운동학회 2019 Journal of Neurogastroenterology and Motility (JNM Vol.25 No.3
Background/AimsThere has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely toupdate the Asian IBS Consensus. MethodsKey opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology,pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process wascarried out by using a modified Delphi method. ResultsThirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-braininteraction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and uppergastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet,probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy. ConclusionsOur consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view toholistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.